Literature DB >> 25346202

Evaluation of PCR-reverse blot hybridization assay for the differentiation and identification of Mycobacterium species in liquid cultures.

H-Y Wang1, H Kim, S Kim, H Bang, D-K Kim, H Lee.   

Abstract

AIMS: The purpose of this study was to evaluate the usefulness of REBA Myco-ID(®) assay based on the principle of reverse blot hybridization assay (REBA) for the rapid detection of Mycobacterium tuberculosis (MTB), the differentiation of MTB from nontuberculous mycobacteria (NTM) and the identification of NTM species in liquid cultures. METHODS AND
RESULTS: A total of 274 mycobacterial liquid cultures that cultured from respiratory specimens including 94 acid-fast bacilli (AFB) smear positives and 180 AFB smear negatives were used in this study. The results of PCR-REBA were compared with those of real-time PCR and PCR-Restriction fragment length polymorphism (RFLP) assays. Sensitivity of 195 MTB and 79 NTM strains determined using DNA isolated from liquid cultures was 100% and 97·5%, respectively. However, two of the liquid culture NTM specimens were not detected by PCR-REBA and were identified as Rhodococcus jostii and R. erythropolis by PRA Myco-ID and rpoB gene sequence analysis. Frequently identified NTM species in the liquid cultures were Mycobacterium avium complex (n = 50, 63·3%) and Mycobacterium abscessus complex (n = 11, 13·9%). The PCR-REBA is able to identify mycobacterial strains more rapidly than conventional tests and does not require specialized instruments and is possible to differentiate between Myc. abscessus and Mycobacterium massiliense strains.
CONCLUSIONS: PCR-REBA assay showed rapid, highly sensitive and specific results for the identification of MTB and NTM and discriminated between NTM species from mycobacterial liquid cultures. SIGNIFICANCE AND IMPACT OF THE STUDY: Even though the use of molecular diagnostic technologies is more expensive than the use of conventional methods, the clinical and economic benefit of saving time in regard to expenses remains to be elucidated. Therefore, the PCR-REBA may provide the essential information to accelerate therapeutic decisions for appropriate antibiotic treatments in the acute phase of mycobacterial diseases.
© 2014 The Society for Applied Microbiology.

Entities:  

Keywords:  Mycobacterium tuberculosis (MTB); Nontuberculous mycobacteria (NTM); PCR-restriction fragment length polymorphism (PCR-RFLP; PRA); REBA Myco-ID®; molecular diagnosis

Mesh:

Year:  2014        PMID: 25346202     DOI: 10.1111/jam.12670

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  6 in total

1.  Clinical characteristics and the diagnostic role of molecular tests in musculoskeletal infections caused by nontuberculous Mycobacterium: a single-center experience.

Authors:  Cheon Hoo Jeon; Si-Ho Kim; Hae Suk Cheong; Dong Hee Kim; Yu-Ji Lee; Eun Phil Heo; Yu Mi Wi
Journal:  Infection       Date:  2022-03-23       Impact factor: 7.455

Review 2.  Pulmonary non-tuberculous mycobacterial infections: current state and future management.

Authors:  Kai Ling Chin; Maria E Sarmiento; Nadine Alvarez-Cabrera; Mohd Nor Norazmi; Armando Acosta
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-12-18       Impact factor: 3.267

Review 3.  The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases.

Authors:  Susan L Baldwin; Sasha E Larsen; Diane Ordway; Gail Cassell; Rhea N Coler
Journal:  PLoS Negl Trop Dis       Date:  2019-02-14

4.  PCR-reverse blot hybridization assay in respiratory specimens for rapid detection and differentiation of mycobacteria in HIV-negative population.

Authors:  Qing Zhang; Heping Xiao; Liping Yan
Journal:  BMC Infect Dis       Date:  2021-03-16       Impact factor: 3.090

5.  The lung microbiota in Korean patients with non-tuberculous mycobacterial pulmonary disease.

Authors:  Sung-Yoon Kang; Hyojung Kim; Sungwon Jung; Sang Min Lee; Sang Pyo Lee
Journal:  BMC Microbiol       Date:  2021-03-18       Impact factor: 3.605

6.  Incidence, Clinical Manifestation, Treatment Outcome, and Drug Susceptibility Pattern of Nontuberculous Mycobacteria in HIV Patients in Tehran, Iran.

Authors:  Seifu Gizaw Feysia; Malihe Hasan-Nejad; Siroos Amini; Gholamreza Hamzelou; Hossein Kazemian; Jalil Kardan-Yamchi; Morteza Karami-Zarandi; Mohammad Mehdi Feizabadi
Journal:  Ethiop J Health Sci       Date:  2020-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.